Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04945850 · ClinicalTrials.gov registry record

Can COVID-19 Persist in Intraocular Fluid?

A clinical trial, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
25
Enrollment target

NCT04945850: Completed study, sponsored by Vanderbilt University Medical Center.

NCT04945850 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04945850 has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
25 participants
Enrollment target

Study Summary

Several common viruses thrive and persist in intraocular fluid due to ocular immune privilege. Immune privilege is maintained by lack of lymphatic tissue, a strong blood ocular barrier, and regulation of the systemic immune response via immunosuppressive factors such as TGF-B and processes like anterior chamber associated immune deviation. Notable viruses that benefit from ocular immune sequestration include DNA viruses such as Herpes simplex virus, Varicella Zoster, Cytomegalovirus and RNA viruses like Ebola and Rubella.In light of the global 2019 Severe acute respiratory syndrome coronavirus-2 virus (SARS CoV-2 or commonly COVID-19) pandemic, there has been growing interest on COVID-19's long term effects on the ocular system. Ocular symptoms at the time of diagnosis and during illness have been reported previously. The most commonly reported are epiphora, chemosis, and conjunctivitis. Less common were findings of retinal hemorrhages and retinal ischemic changes. Recent literature has demonstrated its presence in ocular fluid such as tears and the aqueous humor, but whether this is sustained for an extended period of time has yet to be determined. Long term effects of covid on the neurological system are being identified - large vessel ischemic strokes, cerebral hemorrhages, cranial nerve palsies, and memory loss in young adults are being reported. The persistence of COVID 19 in the intraocular fluid several months after covid infection has not been studied previously.

Primary Outcome

We aim to examine the presence of COVID-19 in the intraocular fluid.

Interventions

  • PROCEDURE routine care intraocular sx

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2021-06-16
Est. Completion 2022-06-16

What the finished NCT04945850 record still lists

NCT04945850 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which routine care intraocular sx is the first listed.

NCT04945850 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04945850 about?

NCT04945850 is a clinical study titled "Can COVID-19 Persist in Intraocular Fluid?". Several common viruses thrive and persist in intraocular fluid due to ocular immune privilege. Immune privilege is maintained by lack of lymphatic tissue, a strong blood ocular barrier, and regulation of the systemic immune response via immunosuppressive factors such as TGF-B and processes like ante...

What is the current status of trial NCT04945850?

This trial is currently completed. The enrollment target is 25 participants. The study started on 2021-06-16. Estimated completion is 2022-06-16.

What interventions are being tested in trial NCT04945850?

The interventions under investigation include: routine care intraocular sx (PROCEDURE).

Who is sponsoring clinical trial NCT04945850?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04945850, the US trial registry maintained by the National Library of Medicine. NCT04945850 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.